Research and Markets (http://www.researchandmarkets.com/research/v238h9/global_alpha) has announced the addition of the "Global Alpha Emitters Market - Growth, Trends and Forecasts (2015 - 2020)" report to their offering.

Alpha emitter radionuclide is considered to be a new approach to tackle cancer and related issues. Alpha emitter provides many advantages when compared to beta emitters and photon therapy, making it an increasingly preferred mode of treatment. As a result, this has caught the attention of major players interested in capitalizing the market potential.

Alpha emitters are currently used in the process of Targeted Alpha Therapy (TAT), where in an alpha emitter radionuclide exposes a certain amount of radiation dose to tumor cells, at a very early stage or in the state of metastasis, and destroy the respective cancer cells. In contrast to chemotherapy, TAT allows easy discrimination between the healthy cells and cancer cells. This is helpful in reducing the side effects associated with Chemotherapy.

Major drivers contributing to growth of the market are increasing incidences of cardiac & cancer ailments, increased awareness about the potential benefits of targeted alpha therapy and increasing availability of radio pharmaceuticals.

Shorter life of radio pharmaceuticals, need for high capital investment, stringent regulatory framework and reimbursement issues are the major factors impacting market growth.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. Market Overview

4. Porters Five Force Analysis

5. Global Alpha Emitters Market Segmentation

6. Competitive Landscape

Companies Mentioned:

  • IBA Group
  • Lantheus Medical Imaging
  • Triad Isotopes
  • Siemens Healthcare (PETNET Solutions)
  • NTP Radioisotopes

For more information visit http://www.researchandmarkets.com/research/v238h9/global_alpha